Hikma Pharmaceuticals Forecast, price target & analysts
Hikma Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Hikma Pharmaceuticals Classifications & Recommendation
Hikma Pharmaceuticals Price Target
| Target Price | £19.38 |
| Price | £16.62 |
| Potential | |
| Number of Estimates | 17 |
| 17 Analysts have issued a price target Hikma Pharmaceuticals 2027 . The average Hikma Pharmaceuticals target price is £19.38. This is higher than the current stock price. The highest price target is , the lowest is . | |
| A rating was issued by 22 analysts: 19 Analysts recommend Hikma Pharmaceuticals to buy, 2 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2027 of . Most analysts recommend the Hikma Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion £ | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? |
15 Analysts have issued a sales forecast Hikma Pharmaceuticals 2026 . The average Hikma Pharmaceuticals sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
15 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2026. The average Hikma Pharmaceuticals EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share £ | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
15 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Hikma Pharmaceuticals...
Current Hikma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| Analyst Rating | Date |
|---|---|
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
